article thumbnail

Bank of England Highlights Concerns With Private Equity Financing

JD Supra: Mergers

The Bank of England’s Financial Policy Committee (FPC) and the Prudential Regulation Authority (PRA) recently delivered a series of speeches1 raising their concerns about the evolution of private equity financing and the banking sector’s exposure to the private equity industry.

article thumbnail

FTC Focus: Private Equity Investments In Healthcare

JD Supra: Mergers

antitrust regulators, particularly the Federal Trade Commission, have been stepping up scrutiny of private equity investments in healthcare. On March 5, the FTC, along with the U.S. Department of Justice and the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FTC Sues Private Equity Firm and Anesthesia Group Alleging Unlawful Monopolization in Texas Market

JD Supra: Mergers

USAP”), and the private equity firm Welsh, Carson, Anderson & Stowe (“Welsh Carson”), which created USAP, executed a multi-year anticompetitive scheme to consolidate anesthesiology practices in Texas, drive up the price of anesthesia services provided to Texas patients and boost their own profits. Anesthesia Partners, Inc.

article thumbnail

2024 Healthcare Private Equity Outlook & Trends

JD Supra: Mergers

As we begin 2024, we have highlighted the issues and trends that private equity (PE) investors should consider when evaluating transactions in the healthcare sector. W ith various headwinds resulting in down volume in 2023, buyers and sellers alike find themselves asking whether 2024 will see a rebound in deal activity.

article thumbnail

The Road Ahead for Private Equity: Reflections and Predictions

JD Supra: Mergers

The year 2023 will be remembered as a challenging one for private equity (PE), with complexities to navigate on many fronts. Although overall transaction volume was significantly down, private equity funds still found. By: Akin Gump Strauss Hauer & Feld LLP

article thumbnail

Antitrust scrutiny of private equity deals intensifies

JD Supra: Mergers

Traditionally, private equity firms were seen as benign investors from an antitrust perspective. This is changing. In the past 12 months, PE-funded acquisitions have faced progressively more rigorous scrutiny by antitrust authorities. By: Allen & Overy LLP

article thumbnail

California’s Private Equity Bill Set for Committee Hearing

JD Supra: Mergers

California’s Senate Appropriations Committee will hold a hearing on California’s private equity bill, AB 3129, on August 15, 2024. This proposed legislation would expand existing California Attorney General authority to include review and approval authority over most healthcare private equity transactions.